慢性リンパ性白血病(CLL)治療薬の世界市場2016-2020...市場調査レポートについてご紹介

【英文タイトル】Global Chronic Lymphocytic Leukemia market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Types of CLL
• Symptoms
• Diagnosis
• Staging
• Management
• Key buying criteria

PART 06: Pipeline analysis
• Acalabrutinib
• TG-1101 + ibrutinib
• TGR-1202
• Venetoclax + obinutuzumab
• Venetoclax + rituximab
• REVLIMID
• Duvelisib

PART 07: Market landscape
• Global CLL therapeutics market
• Total addressable market for global CLL therapeutics
• Five forces analysis

PART 08: Market segmentation by ROA
• Oral
• Parenteral

PART 09: Market segmentation by type of molecule
• Small molecules
• Biologics

PART 10: Geographical segmentation
• Global CLL therapeutics market by geographical segmentation 2015-2020
• CLL therapeutics market in Americas
• CLL therapeutics market in EMEA
• CLL therapeutics market in APAC

PART 11: Market drivers
• Special regulatory designations
• Recent drug approvals
• Application for expanded indication approvals
• Increase in patient pool

PART 12: Impact of drivers

PART 13: Market challenges
• High cost of therapy
• Availability of chemotherapy and off-label drugs
• Adverse effects of drugs
• Stringent regulatory guidelines

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Joint ventures and partnerships
• Patient assistance programs
• Rise in development of combination therapies
• Growing public awareness

PART 16: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• F. Hoffmann-La Roche
• AbbVie
• Teva Pharmaceuticals
• Johnson & Johnson
• Gilead Sciences
• Novartis
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Timeline of development of leukemia drugs
Exhibit 03: Snapshot of CLL
Exhibit 04: Types of CLL
Exhibit 05: Main diagnostic procedures to determine presence of CLL
Exhibit 06: Other diagnostic procedures to determine presence of CLL
Exhibit 07: Rai stages of CLL
Exhibit 08: Binet stages of CLL
Exhibit 09: Management of CLL
Exhibit 10: Key buying criteria for CLL drugs
Exhibit 11: Pipeline portfolio: Global CLL therapeutics market
Exhibit 12: Percentage share of drug candidates by stage of development 2015
Exhibit 13: Global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 14: Total addressable market for global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 15: Five forces analysis
Exhibit 16: Segmentation of global CLL therapeutics market by ROA 2015
Exhibit 17: Segmentation of global CLL therapeutics market by type of molecule 2015
Exhibit 18: Segmentation of global CLL therapeutics market based on geography 2015
Exhibit 19: Segmentation of global CLL therapeutics market based on geography 2020
Exhibit 20: Global CLL therapeutics market by geography 2015-2020 ($ millions)
Exhibit 21: Global CLL therapeutics market by geography 2015-2020
Exhibit 22: CLL therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 23: CLL therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 24: CLL therapeutics market in APAC 2015-2020 ($ millions)
Exhibit 25: Global CLL therapeutics market: YoY growth and revenue based on geography 2015-2020
Exhibit 26: Population aged 60 years and over: World, developed, and developing regions (millions)
Exhibit 27: Impact of drivers
Exhibit 28: Cost of therapy for CLL
Exhibit 29: Impact of drivers and challenges
Exhibit 30: SWOT: MabThera
Exhibit 31: SWOT: Imbruvica
Exhibit 32: SWOT: Treanda
Exhibit 33: SWOT of Zydelig
Exhibit 34: F. Hoffmann-La Roche: YoY growth and revenue generated from total product sales of MabThera/Rituxan (oncology indication) 2013-2015 ($ billions)
Exhibit 35: MabThera/Rituxan geographic segmentation by revenue 2015
Exhibit 36: F. Hoffmann-La Roche: Key takeaways
Exhibit 37: AbbVie: Key takeaways
Exhibit 38: Teva Pharmaceuticals: YoY revenue and growth rate of Treanda 2013-2015 ($ millions)
Exhibit 39: Teva Pharmaceuticals: Key takeaways
Exhibit 40: Johnson & Johnson: YoY revenue comparison of Imbruvica (Global) 2013-2015 ($ millions)
Exhibit 41: Johnson & Johnson: YoY revenue comparison of Imbruvica (US) 2013-2015 ($ millions)
Exhibit 42: Johnson & Johnson: YoY revenue comparison of Imbruvica (ROW) 2013-2015 ($ millions)
Exhibit 43: Johnson & Johnson: Geographic segmentation of Imbruvica 2015
Exhibit 44: Johnson & Johnson: Key takeaways
Exhibit 45: Gilead Sciences: YoY revenue and growth rate of Zydelig 2013-2015 ($ millions)
Exhibit 46: Gilead Sciences: Key takeaways
Exhibit 47: Novartis: Key takeaways


【レポート販売概要】

■ タイトル:慢性リンパ性白血病(CLL)治療薬の世界市場2016-2020
■ 英文:Global Chronic Lymphocytic Leukemia market 2016-2020
■ 発行日:2016年6月1日
■ 調査会社:Technavio
■ 商品コード:IRTNTR9378
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。